SCHEMBL14745837

SCHEMBL14745837

COc1ccc(C/N=C2/CCCN(C(=O)OC(C)(C)C)c3cc4c(cc32)cc(CO[Si](C)(C)C(C)(C)C)n4C)c(OC)c1

nearest known ligand 0.35

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
P2RX3 P56373 1/20 0.35
KMT2A Q03164 2/20 0.33
MEN1 O00255 1/20 0.33
ALDH1A1 P00352 3/20 0.32
KDM4E B2RXH2 1/20 0.32
MAPT P10636 3/20 0.32
HPGD P15428 2/20 0.32
TSHR P16473 2/20 0.32
LMNA P02545 2/20 0.32
PLA2G1B P04054 1/20 0.32
ATG4B Q9Y4P1 1/20 0.32
MPO P05164 1/20 0.31
TLR9 Q9NR96 2/20 0.31
TLR7 Q9NYK1 2/20 0.31
HSD17B10 Q99714 1/20 0.31
EPHX2 P34913 1/20 0.30
STS P08842 1/20 0.30
RAB9A P51151 1/20 0.30
F10 P00742 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14745839 1.00 P2RX3 (0.35) P2RX3KMT2AMEN1ALDH1A1KDM4E
SCHEMBL14745885 0.98 P2RX3 (0.35) P2RX3KMT2AMEN1ALDH1A1KDM4E
SCHEMBL14745883 0.98 P2RX3 (0.35) P2RX3KMT2AMEN1ALDH1A1KDM4E
SCHEMBL14741285 0.82 NPC1 (0.33) KMT2AKDM4EMAPTLMNARAB9A
SCHEMBL14746179 0.82 NPC1 (0.33) KMT2AKDM4ELMNARAB9A
SCHEMBL16428543 0.82 NPC1 (0.33) KMT2AKDM4EMAPTLMNARAB9A
SCHEMBL14746177 0.82 NPC1 (0.33) KMT2AKDM4ELMNARAB9A
SCHEMBL14741432 0.82 LMNA (0.33) LMNAHSD17B10RAB9A
SCHEMBL16428823 0.82 LMNA (0.33) LMNAHSD17B10RAB9A
SCHEMBL16428740 0.81 P2RX3 (0.35) P2RX3KMT2AMEN1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2750678-B1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE PTC THERAPEUTICS INC (US) 2017-03-22 EP disclosed
US-20150038438-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE PTC THERAPEUTICS, INC. 2015-02-05 US disclosed
EP-2750678-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE PTC Therapeutics, Inc. (US) 2014-07-09 EP disclosed
WO-2013033228-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE PTC THERAPEUTICS, INC. (US) 2013-03-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150038438-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE MRPL21, SLC11A2, CLPP P2RX3 3360/4885KMT2A 4450/4885MEN1 4630/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.